Trial site
Zangmeister Cancer Center
Columbus, Ohio 43219, United StatesNot linked to an institution yet
- 10running trials
- 6closed trials
The trials here
What the 16 trials at this site are about, from their registry records.
- Phase
- Phase 27 trials
- Phase 36 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 41 trial
- Status
- Active, not recruiting7 trials
- Completed4 trials
- Recruiting3 trials
- Terminated1 trial
- Withdrawn1 trial
- Lead sponsor
- Gilead Sciences2 trials
- AbbVie1 trial
- Compass Therapeutics1 trial
- Genmab1 trial
- Karyopharm Therapeutics Inc1 trial
- and 10 more
Running trials
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270· Phase 3· Genmab· Source
Recruiting
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543· Phase 4· Takeda· Source
Contact: Sameh Mikhail (principal investigator)
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505· Phase 2· Puma Biotechnology, Inc.· Source
Contact: Puma Biotechnology, Inc. Clinical Operations Senior Director
Active, not recruiting
Phase III Study of AK112 for NSCLC Patients
NCT06396065· Phase 3· Summit Therapeutics· Source
Active, not recruiting
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931· Phase 3· Karyopharm Therapeutics Inc· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Active, not recruiting
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526· Phase 1/2· OncoC4, Inc.· Source
Active, not recruiting
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013· Phase 1· Tizona Therapeutics, Inc· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689· Phase 2· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, INC
Completed
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
NCT05513742· Phase 2· Compass Therapeutics· Source
Completed
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
NCT05054725· Phase 2· Revolution Medicines, Inc.· Source
Terminated
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811· Phase 2· NeoImmuneTech· Source
Completed
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
NCT04620330· Phase 2· Verastem, Inc.· Source
Completed
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
NCT04209855· Phase 3· AbbVie· Source
Report an error